NVIDIA CorporationNvidia fell more than 2% premarket after AI executives called for slowing model development.
U.S. stock index futures fell sharply on Monday, with technology shares under pressure after several leading artificial intelligence executives called for a slower pace of AI development. By 05:52 ET, Dow futures had fallen 150 points, or 0.3%, S&P 500 futures had dropped 63 points, or 0.8%, and Nasdaq 100 futures had slumped 531 points, or 1.8%. Rumble shares surged as much as 28% in premarket trading after reports that Anthropic had agreed to a $13.7 billion computing contract with the company, a deal Rumble had disclosed in an August securities filing without identifying the customer. Anthropic CEO Dario Amodei called on AI companies to slow the advancement of model capabilities in an essay posted on X on Saturday, warning that increasingly capable AI agents could create significant economic damage if misused, and OpenAI CEO Sam Altman and xAI chief Elon Musk said they agree with his concerns. Nvidia fell more than 2% in premarket trading, while Meta and Amazon each dropped more than 1%, and chipmakers Intel, AMD and Marvell Technology fell nearly 6%, 5% and 6%, respectively, even as software names ServiceNow, Adobe and Workday rose about 3%, 2.5% and 2.5%. Scholar Rock shares surged 9.1% to $60.45 after the FDA approved ISEMBYLD, also known as apitegromab-mstn, as the first and only muscle-targeted treatment for spinal muscular atrophy in patients aged two and older receiving an SMN2-targeted therapy, ahead of the September 30, 2026 PDUFA deadline. Elmet Group shares jumped 30.8% after announcing a $450 million committed investment from the U.S. Department of War to accelerate domestic tungsten manufacturing, while Olema Pharmaceuticals slid 15.1% to $8.68 after AstraZeneca said its Phase 3 SERENA-4 trial of camizestrant failed to show a statistically significant improvement in progression-free survival, and MARA Holdings fell 5.7% to $11.30 after JPMorgan double-downgraded the bitcoin miner to Underweight from Neutral and cut its price target to $11 from $13.
NVIDIA CorporationNvidia fell more than 2% premarket after AI executives called for slowing model development.
Marvell Technology Group LtdMarvell fell nearly 6% premarket as AI executives urged slower AI development, pressuring chipmakers.
Advanced Micro Devices IncAMD fell nearly 5% as AI executives urged slowing AI development, pressuring chipmakers tied to AI buildout.
ServiceNow IncServiceNow rose about 3% as software names gained while chipmakers slid amid the AI slowdown calls.
Amazon.com IncAmazon dropped more than 1% amid broad AI-related tech weakness after executives called for slower AI development.
Adobe Systems IncorporatedAdobe rose about 2.5% as software names gained while AI chipmakers slid, a sector rotation favoring software over AI hardware.
Scholar Rock Holding CorpFDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-targeted treatment for spinal muscular atrophy, ahead of the PDUFA deadline.
AstraZeneca PLCAstraZeneca said its Phase 3 SERENA-4 trial of camizestrant failed to show a statistically significant result.
Olema Pharmaceuticals IncOlema slid 15.1% after AstraZeneca's Phase 3 SERENA-4 trial of camizestrant failed to show statistical significance.
JPMorgan Chase & Co
MARA Holdings Inc
Marathon Digital Holdings Inc
Rumble Inc.Rumble surged as much as 28% after Anthropic agreed to a $13.7 billion computing contract with the company.
Workday Inc
The Elmet Group Co. Common StockElmet announced a $450 million committed investment from the U.S. Department of War to accelerate domestic tungsten manufacturing.
Intel CorporationIntel fell nearly 6% as AI executives' call to slow development pressured chipmakers.
Meta Platforms Inc.Meta dropped more than 1% amid AI-stock weakness following executives' calls for slower AI development.